

Synthesis and evaluation of *in vitro* antibacterial properties of secoisolariciresinol diglucoside

ABSTRACT

In the present study, Secoisolariciresinol diglucoside (SDG) was synthesized from commercially available 3,4-dimethoxytoluene, butanediol and penta acetyl glucose. This includes bromination, alkylation, glycosylation, deacetylation and demethylation reactions to yield the interested title compound (SDG). Further, the assignment of the chemical structure of the synthetic SDG was performed with IR, MS-TOF, ^1H and ^{13}C NMR. The antibacterial property of the synthetic SDG was investigated against seven different Gram positive and Gram negative bacteria. The results of the present study proved that SDG can be obtained with good yield (56.2%) under this scheme. Moreover, it exerts an exceptional antibacterial activity where it showed maximum zone of inhibition with 30 and 27.3 mm against *E. coli* and minimum 7 and 6.1 mm against *S. pyogens* and *S. typhimurium* in agar well and disk diffusion respectively. It also showed maximum activity (18 mm at MIC 200 ppm) against *S. typhimurium*, while minimum inhibitory activity was 4 mm with MIC at 300 ppm against *S. pyogens*. The scheme of synthesis was found to be an efficient method and the synthetic SDG was also proved to possess a broad spectrum of activity against a panel of bacteria responsible for causing most common diseases.

Keywords: Synthetic secoisolariciresinol diglucoside, IR, MS-TOF, ^1H and ^{13}C NMR and Anti-bacterial Activity.

1. INTRODUCTION

With the development and clinical use of antibiotics in the nineteenth century, there has been a drastic reduction in the incidences of bacterial infections diseases, which were a leading cause of human mortality world-wide. But, there has been an alarming increase in bacterial resistance to the present chemotherapeutic agents largely due to their injudicious use and this has turned out to be an issue of global concern [1,2]. Emergence of multidrug-resistant pathogens threatened the clinical efficacy of many existing antibiotics [3], leading the scientists to increasingly turn their attention to finding out new antimicrobial compounds with diverse chemical structures and novel mechanisms of action for the new infectious diseases [4]. Phytoestrogens have been found *via* several *in vivo* and *in vitro* studies to exert a potent biological activity besides their major estrogenic and anti-estrogenic activities due to their structural similarity with estrogens [5,6]. Lignans are second major class of phytoestrogens that have been proved to exert antioxidant, anti-inflammatory, anticancer, anti-diabetic and many other biological properties. Isoflavones and coumestans are the other classes of phytoestrogens [7]. Lignans are natural poly phenolic compounds which have long been recognized as challenging targets for organic synthesis due to their complex and diverse chemical structure as well as their important pharmacological properties. Epidemiological studies have reported the chemo preventive effects of lignans on tumors of colon, skin and mammary glands [8]. Lignans also exert antibacterial and cytotoxic activities [9]. Lignans also showed antimicrobial activity against several important pathogenic bacteria with different minimum inhibitory concentrations for each microorganism [10]. Additionally, there are not any reports on side effects and toxicity on lignan usage [11]. Flaxseed, the richest source of SDG, has gained importance in food industry as a component in designer food, functional food and in value added products because of its high content of lignans, which exert nutraceutical and therapeutic properties [12]. SDG from different cultivars of Indian flax seed have been found to exert potential anti-bacterial activity against microbial pathogens [13]. It is also found to possess potential properties such as both *in vivo* and *in vitro* antioxidant activities [14], anti-diabetic type I and II [15], anti-cancer effect on the breast [16], prostate [17], and anti-inflammatory agents [18].

It is believed that isolation of SDG from natural sources is a very laborious, sensitive and time consuming process. Additionally, isolation methods involve use of chemicals and reagents which may cause deleterious effects on animals including humans [19]. Apart from this, the yield of the product is less on isolation, purity will not be 100% and bioavailability of this SDG is low in animals [20]. Moreover, isolated and commercially available SDG is quite expensive. Lignan synthesis relies on limited number of integral reactions that are required for the construction of the basic 18-carbon skeleton whose modification (e.g. cyclization, reduction, oxidation and hydration) can generate the entire set of lignan compounds. Despite their attractive and proven biological properties, only few studies have approached the chemical synthesis of lignans, for instance alphahydroxylated lactone lignans [21], benzopyran [22], erythronordihydroguaiaretic acid [23] and olive type lignans [24]. Therefore, the objective of the present investigation was to design, synthesize and corroborate the antibacterial activity of SDG, a principal lignan of flaxseed against a panel of Gram positive and Gram negative bacteria responsible for causing the most prevalent infectious diseases.

2. Material and methods

The chemicals used were purchased from Sigma Aldrich, USA and the general solvents used in the experiments were of analytical grade. Melting points were determined by using open capillary method with KOFER Microscope and are uncorrected, IR spectra were obtained in (cm^{-1}) JASCO FT-IR spectrometer using KBr pellet technique. ^1H and ^{13}C NMR spectra were recorded (in ppm) on BRUKER AV 400MHz spectrometer using deuterated methanol as solvent and TMS as internal standard. Mass Spectroscopy analysis was carried out by ESI-TOF MS. Elemental analysis was performed on a Perkin Elmer 2400 Elemental Analyser to confirm the structure of the synthetic compounds. Flash column chromatography was generally performed on silica gel (60 - 200 mesh) for purification of the compounds with the solvent mixture of chloroform/hexane. Precoated alumina with silica gel 60 F_{254} (E. Merck) plates were used for monitoring of reactions and purity determination. Spots were detected by UV (254 nm).

2.1. Chemistry

Synthesis of SDG was reported in this researcher's earlier study wherein the yield was less from the adopted scheme [25]. Therefore, herein a new scheme was designed for the synthesis of SDG. The chemical synthesis of SDG was accomplished through a novel five-step synthesis sequence (Fig. 1) starting from the bromination of the commercially available compound 3,4-dimethoxytoluene (**1**) with N-bromosuccinimide (NBS) in the presence of carbon tetrachloride to achieve 1,2-dimethoxy-4-bromomethylbenzene (**2**). 2,3-bis (3,4-dimethoxybenzyl) butane-1,4-diol (**3**) was afforded by stirring compound **2** with 1,4-butanediol in the presence of n-butyl lithium in 15 mL of DMF. Condensation of compound **3** with 2,3,4,6-tetra-O-acetyl- α -D-glucopyranosyl bromide in presence of catalytic amount of 2N hydrochloric acid and ethanol as solvent gave 2,3- bis (3,4-dimethoxybenzyl)butane-1,4-O-tetra acetyl glucopyranoside (**4**). Compound, 2,3-bis(3,4-dimethoxybenzyl)butane-1,4-O-glucose (**5**) was obtained in good yield by deacetylation of compound **4** with sodium hydroxide in presence of ethanol. Finally, the synthesis of the title compound (**6**), i.e. secoisolariciresinol diglucoside (SDG) was attained via regioselective partial demethylation of compound **5** using stannous chloride in presence of dichloromethane and 2N hydrochloric acid.

Synthesis of 1,2-dimethoxy-4-bromomethylbenzene (**2**)

The 3,4-dimethoxytoluene (**1**) was selectively brominated according to the regioselective method of Hong *et al* [26]. using NBS as brominating agent. NBS (5.83 g, 32.80 mmol) was added to a stirred solution of 3,4-dimethoxytoluene (5.00 g, 32.80 mmol) in 70 mL of CCl_4 and the reaction mixture was refluxed for 11 h. The reaction mixture was cooled; succinimide was filtered off and washed with CCl_4 . The solvent was evaporated under reduced pressure to yield the crude product (**2**). Recrystallization from the mixture of hexane and diethyl ether (1:1) afforded white needles of compound **2**.

Yield: 5.054 g (66.6%), mp 50.0 - 52.1 °C. $^1\text{H-NMR}$ (CD_3OD) δ 6.90 (H, d, J = 7.5 Hz, $\text{C}_2\text{-H}_{\text{arom}}$), 6.76 (H, d, J = 8.1 Hz, $\text{C}_5\text{-H}_{\text{arom}}$), 6.68 (H, d, J = 7.8 Hz, $\text{C}_6\text{-H}_{\text{arom}}$), 4.54 (H, s, $\text{C}_1\text{-H}$), 3.38 (6H, s, 2 $-\text{OCH}_3$). $^{13}\text{C-NMR}$ (CD_3OD) 150.1 (C_4), 150 (C_3), 131(C_1), 122.1 (C_6), 114 (C_2), 112.5 (C_5), 33.6 (C_7). MS: m/z 231.0874 ($\text{M} + 1$). $\text{C}_9\text{H}_{11}\text{BrO}_2$ (231.09) Anal. Cal. C, 46.78; H, 4.80. Found: C, 46.72; H, 4.78.

Synthesis of 2,3-bis (3,4-dimethoxybenzyl)butane-1,4-diol (**3**)

The alkylation of compound **2** was carried out based on the modified procedure of Garonski and Garonska [25]. One equivalent of compound **2** (0.97 g, 10.67 mmol) was added to butanediol (5.00 g, 21.60 mmol) and n-butyl lithium (2.20 g, 16.00 mmol) in 15 mL of DMF. The mixture was stirred at (- 60 °C to 05 °C) for 3 h and then the reaction mixture was stirred at 20 °C for 10 h. The reaction mixture was cooled to room temperature, extracted with hexane (3 × 30 mL), and the solvent was evaporated to yield compound **3** (Oil).

Yield: 3.50 g (83.8%), IR (nujol, cm^{-1}): 3430, 3320 (OH). ^1H NMR (CD_3OD) δ 6.83 (2H, d, J = 8.2 Hz, $\text{C}_{5,5'}\text{-H}_{\text{arom}}$), 6.78 (2H, d, $\text{C}_{2,2'}\text{-H}_{\text{arom}}$), 6.70 (2H, dd, J = 1.9, 8.0 Hz, $\text{C}_{6,6'}\text{-H}_{\text{arom}}$), 3.85 (3H, s, OCH_3), 3.64 (2H, dd, J = 7.6, 7.8 Hz, 2 -OH), 3.62 (2H, dd, J = 5.6, 9.5 Hz, $\text{C}_{9a,9a'}\text{-H}_{\text{aliph}}$), 3.37 (2H, dd, J = 6.6, 9.8 Hz, $\text{C}_{9b,9b'}\text{-H}_{\text{aliph}}$), 2.62 (2H, dd, J = 8.1, 13.6 Hz, $\text{C}_{7a,7a'}\text{-H}_{\text{aliph}}$), 2.40 (2H, dd, J = 6.9, 13.7 Hz, $\text{C}_{7b,7b'}\text{-H}_{\text{aliph}}$), 1.92 (2H, m, $\text{C}_{8,8'}\text{-H}_{\text{aliph}}$). ^{13}C NMR (CD_3OD) 149.2 ($\text{C}_{3,3'}$), 147 ($\text{C}_{4,4'}$), 132 ($\text{C}_{1,1'}$), 122.4 ($\text{C}_{6,6'}$), 113.4 ($\text{C}_{2,2'}$), 112.6 ($\text{C}_{5,5'}$), 65.6 ($\text{C}_{9,9'}$), 56.2 (C-OCH₃), 42.8 ($\text{C}_{8,8'}$), 35.3 ($\text{C}_{7,7'}$). MS: m/z 390.4721 ($M+1$). $\text{C}_{22}\text{H}_{30}\text{O}_6$ (390.47) Anal. Cal. C, 67.67; H, 7.74. Found: C, 67.51; H, 7.66.

Synthesis of 2,3-bis (3,4 -dimethoxybenzyl)butane-1,4-*O*-tetra acetyl glucose (**4**)

Compound **3** (3.50 g, 9.00 mmol) was added to a solution of 2,3,4,6 tetra-*O*-acetyl α -D glucopyranosyl bromide (7.12 g, 18.00 mmol) in 10 mL ethanol. The reaction mixture was stirred and refluxed for 19 h. After the completion of the reaction monitored by TLC, the reaction mixture was kept overnight to achieve crystalline product. Finally, the crystalline product was extracted with ether (3 × 30 mL), and the ether layer was passed through anhydrous sodium sulphate. The ether was evaporated and the product was recrystallized from the mixture of hexane and diethyl ether (1:1) to give compound **4** as white crystalline solid.

Yield: 5.07 g (52.9%), mp 65 - 66.2 °C, IR (nujol, cm^{-1}): 1710 (C=O for COO). ^1H NMR (CD_3OD) δ 6.83 (2H, d, J = 8.0 Hz, $\text{C}_{5,5'}\text{-H}_{\text{arom}}$), 6.78 (2H, d, J = 1.8 Hz, $\text{C}_{2,2'}\text{-H}_{\text{arom}}$), 6.74 (2H, dd, J = 1.8, 8.1 Hz, $\text{C}_{6,6'}\text{-H}_{\text{arom}}$), 3.80 (3H, s, OCH_3), 3.65 (2H, d, J = 7.1 Hz, $\text{C}_{9,9'}\text{-}\beta\text{-O-Glu}$ anomeric), 3.62 (2H, dd, J = 5.4, 10 Hz, $\text{C}_{9a,9a'}\text{-H}_{\text{aliph}}$), 3.38 (2H, dd, J = 6.5, 10 Hz, $\text{C}_{9b,9b'}\text{-H}_{\text{aliph}}$), 2.20 - 4.52 (38H, $\text{C}_{9,9'}\text{-O-Glu}$), 2.60 (2H, dd, J = 8.6, 13.8 Hz, $\text{C}_{7a,7a'}\text{-H}_{\text{aliph}}$), 2.41 (2H, dd, J = 8.2, 13.4 Hz, $\text{C}_{7b,7b'}\text{-H}_{\text{aliph}}$), 2.18 (2H, m, $\text{C}_{8,8'}\text{-H}_{\text{aliph}}$). ^{13}C NMR (CD_3OD) 149.2 ($\text{C}_{3,3'}$), 147 ($\text{C}_{4,4'}$), 132 ($\text{C}_{1,1'}$), 122.6 ($\text{C}_{6,6'}$), 113.2 ($\text{C}_{2,2'}$), 112.6 ($\text{C}_{5,5'}$), 72.7 ($\text{C}_{9,9'}$), 59.8

128 (C9,9'-O-Glu anomeric), 56.1 (C-OCH₃), 39.7 (C7,7'), 37.8 (C8,8'), 20.8 - 170.0 (C9,9'-O-Glu). MS: m/z
129 1051.0498 (M + 1). C₅₀H₆₆O₂₄ (1051.04) Anal. Cal. C, 57.14; H, 6.33. Found: C, 56.42; H, 6.65.

130 **Synthesis of 2,3-bis (3,4-dimethoxybenzyl) butane-1,4 -O- glucose (5)**

131 Deacetylation of compound **4** (5.00 g, 4.76 mmol) was achieved by adding 0.75 g NaOH in 10 mL water
132 and 15 mL ethanol. The reaction mixture was stirred and refluxed on water bath for 30 min. The reaction
133 mixture was cooled to room temperature and the crude product was extracted with diethyl ether (3 × 30
134 mL), and the ether layer was passed through anhydrous sodium sulphate. The solvent was evaporated to
135 yield compound **5** as a pasty mass.

136 Yield: 2.01 g (59.23%), IR (nujol, cm⁻¹): 3200, 3400 (OH). ¹H NMR (CD₃OD) δ 6.80 (2H, d, J= 8.2 Hz,
137 C_{5,5'}-H_{arom}), 6.78 (2H, dd, J= 1.8 Hz, C_{2,2'}-H_{arom}), 6.76 (2H, dd, J= 2,8.0 Hz, C_{6,6'}-H_{arom}), 4.2 (2H, d, J=
138 7.1, C_{9,9'}-β-O Glu anomeric), 3.83 (3H, s, OCH₃), 3-3.8 (22H, m, C_{9,9'}-O-Glu), 3.44 (2H, dd, J= 5.6, Hz,
139 C_{9a,9a'}-H_{aliph}), 3.20 (2H, dd, J= 6.5, 10 Hz, C_{9b,9b'}-H_{aliph}), 2.64 (2H, dd, J= 8.4, 13.8 Hz, C_{7a,7a'}-H_{aliph}), 2.38
140 (2H, dd, J= 8.4, 13.6 Hz, C_{7b,7b'}-H_{aliph}), 2.18 (2H, m, C_{8,8'}-H_{aliph}). ¹³C NMR (CD₃OD) 149.1 (C3,3'), 147
141 (C4,4'), 132.4 (C1,1'), 122.6 (C6,6'), 113.3 (C2,2'), 112.4 (C5,5'), 104 (C9,9'-O-Glu anomeric), 71.8
142 (C9,9'), 64 - 79.5 (C9,9'-O-Glu), 56.2 (C-OCH₃), 40.6 (C8,8'), 39.8 (C7,7'),. MS: m/z 714.7548 (M+ 1).
143 C₃₄H₅₀O₁₆ (714.75) Anal. Cal. C, 57.13; H, 7.05. Found: C, 58.50; H, 7.86.

144 **Synthesis of secoisolariciresinol diglucoside (6)**

145 Partial demethylation of compound **5** was carried out according to the regioselective method of Arvind *et*
146 *al* [27]. with minor modification in the reagent quantities. To a solution of compound **5** (1.90 g, 2.66 mmol)
147 in 20 mL of dichloromethane, stannous chloride (1.00 g, 5.27 mmol) was added. The reaction mixture
148 was stirred for 3 h at 40 °C. Then 10 mL of 2 N HCl was added to the reaction mixture and stirring was
149 continued for 10 min to obtain the crude demethylated compound **6**. The reaction mixture was washed
150 with water (3 × 25 mL), the organic layer was dried over anhydrous sodium sulphate, and the solid
151 product was chromatographed using silica gel column and hexane/chloroform (1:1) as eluent to obtain
152 yellow crystal of title compound **6** with chemical structure represented in Scheme 1.

153 Yield: 1.30 g (56.2%) mp 119 - 121 °C (literature m.p118 - 120 °C). IR (nujol, cm⁻¹): 3150, 3450 (OH). ¹H-
154 NMR (CD₃OD) δ 6.6 (2H, d, J= 2 Hz, C_{2,2'}-H_{arom}), 6.64 (2H, d, J= 8.1 Hz, C_{5,5'}-H_{arom}), 6.54 (2H, dd, J= 2,

155 8.1 Hz, C_{6,6'}-H_{arom}), 4.22 (2H, d, J= 7.8 Hz, C_{9,9'}-β-O Glu anomeric), 4.1 (2H, dd, J= 5.6, 10 Hz, C_{9a,9a'}-H
 156 aliph), 3.73 (2H, s, OCH₃), 3.48 (2H, dd, J= 6.5, 9.9 Hz, C_{9b,9b'}-H_{aliph}), 3.12 - 3.94 (22H, m, C_{9,9'}-O-Glu) 2.7
 157 (2H, dd, J= 7, 13.8 Hz, C_{7b,7b'}-H_{aliph}), 2.62 (2H, dd, J= 8.2, 13.8 Hz, C_{7a,7a'}-H_{aliph}), 2.10 (2H, m, C_{8,8'}-H
 158 aliph). ¹³C-NMR (CD₃OD) δ 148.8 (C3/3'), 145.4 (C4/4'), 134 (C1/1'), 123 (C6/6'), 115.5 (C5/5'), 113.7
 159 (C2/2'), 104.8 (C-O-Glu'), 71.4 (C9/9'), 62.7 - 78.3(C9/9'-O- Glu.), 56.4 (C-OCH₃), 41.2 (C8/8'), 35.8
 160 (C7/7'). MS: m/z: 686.7014 (M + 1). C₃₂H₄₆O₁₆ (686.71) Anal. Cal. C, 55.97; H, 6.75. Found: C, 57.88; H,
 161 7.80.

162 2.2. Determination of antibacterial effects

163 The antibacterial activity of the synthetic SDG was tested against *Salmonella typhimurium* (MTCC 98),
 164 *Escherichia coli* (MTCC 40), *Shigella flexineri* (H57), *Staphylococcus aureus* (MTCC 96), *Xanthomonas*
 165 (XL), *Bacillus subtilis* (MTCC 619), and *Streptococcus pyogens* (1925) which were obtained from the
 166 stock culture maintained at Department of Studies in Microbiology, University of Mysore, Mysore, India.

167 All the MTCC cultures employed in this current task were maintained on nutrient agar slants (Hi Media
 168 chemicals, India) and preserved at 4 °C. 24 h of broth cultures of *S. typhimurium*, *E. coli*, *S. flexineri*, *S.*
 169 *aureus*, *Xanthomonas*, *B. subtilis*, and *S. pyogens* were prepared by inoculating the bacterial pathogens
 170 in nutrient broth (Hi-Media chemicals, India) and incubated at 28 °C. Spread plate method was followed
 171 by inoculating 100μL of broth cultures on a nutrient agar plate.

172 The agar medium was purchased from Hi-Media laboratories Ltd., Mumbai, India. Nutrient broth,
 173 subculture, base layer medium, agar medium and peptone water were prepared as per the standard
 174 procedure.

175 a. Agar-well diffusion assay

176 The antimicrobial activity was measured by agar well diffusion assay following the method of Bauer *et al*
 177 [28]. Sample dissolved in ethanol (2.5 mg/mL) was used for the assay. The wells were prepared in the
 178 plates with the help of a cork-borer (0.85 cm). About 50 μL of the test compound was introduced into the
 179 wells and allowed to diffuse for 2 h at 4 °C. Plates were incubated at 37 °C for 48 h and the microbial
 180 growth was determined by measuring the diameter of inhibition zones. Methanol alone was used as a

negative control and streptomycin as a positive control. The assay was carried out in triplicate and the mean values are presented.

b. Agar–disc diffusion method

Synthetic SDG was screened for antimicrobial activity by disc diffusion based on the method of Parekh *et al* [29]. using Mueller-Hinton agar medium to study the preliminary antibacterial activity against *S. typhimurium*, *E. coli*, *S. flexineri*, *S. aureus*, *Xanthomonas*, *B. subtilis*, and *S. pyogens*. Synthetic SDG was dissolved in 5mL of dimethyl sulfoxide (DMSO) (1000 ug/mL). 0.1 mL of this compound was introduced on the disc (0.7 cm) (Hi-Media) and allowed to dry. Then the disc was impregnated on the seeded agar plate. DMSO was used as a negative control, whereas, Streptomycin was used as a positive control. The plates were done in triplicates and were incubated. The antimicrobial activity was taken on the basis of the diameter of zone of inhibition.

c. Minimum Inhibitory Concentration (MIC)

The MIC was determined by the modified method of Dufour *et al.*, and Gary *et al* [30,31] Different concentrations (100 ppm to 300 ppm) of synthetic SDG and Chloramphenicol standard (positive control) and 100 µL of the bacterial suspension (10^5 CFU/mL) were placed aseptically in 10 mL of nutrient broth and incubated for 24 h at 37 °C. The growth was observed both visually and by measuring O.D. at 600 nm at regular intervals followed by plating with nutrient agar. The lowest concentration of test sample showing no visible growth was recorded as the minimum inhibitory concentration. Sample tubes were maintained for each concentration of test sample and the readings were plotted against O.D at 600 nm as growth curves.

3. Results and discussion

3.1. Chemistry

The reaction sequence for title compound 6 was outlined in **Scheme 1**. This synthesis begins with the regioselective bromination of the commercially available compound **1** (3,4-dimethoxy toluene) obtained from Sigma Aldrich Chemicals Co. (St. Louis, MO, USA). Compound **3** was achieved by the alkylation of compound **2** with butanediol. The methoxy groups in compound **3** played an important role in hindering

the condensation reaction with pentaacetyl glucose which occurs at phenyl rings. Finally, compound **6** was achieved by the deacetylation and partial demethylation of compound **4** and **5** respectively. All the synthetic compounds were obtained in moderate yield and their structures were confirmed by IR, NMR and MS-TOF. The current synthesis scheme of SDG was found to be an efficient approach. The great advantage of this approach is that the compounds used are readily synthesized in quick time with less quantity of chemicals. Moreover, a good yield of the titled compound was achieved in this approach for the first time in contrast to previous procedures. Furthermore, purification process needed less time, as all the starting materials can be removed easily by flash chromatography, and purification of the products can be carried out by column chromatography.

3.2. Antibacterial activities

a. Agar-well diffusion assay

The antibacterial activity of synthetic SDG was evaluated *in vitro* by agar well diffusion method against seven bacterial species. It exhibited significant antibacterial activity against all tested bacterial strains with various degrees of inhibition. The maximum activity (30 mm) was against *E. coli*, whereas, it was minimum (7 mm) against *S. pyogens*. On the other hand the activity was moderate for the rest of the tested bacterial strains as shown in Table (1) below.

b. Agar-disc diffusion method

The evaluation of the antibacterial activity of synthetic SDG was also carried out using another *in vitro* method which is agar disc diffusion. Disc diffusion methods are extensively used to investigate the antibacterial activity of synthetic compounds, natural substances and plant extracts. These assays are based on the use of discs as reservoirs containing solutions of substances to be examined.

The synthetic SDG was found to exert high and most pronounced antibacterial activity with inhibition zone of 27.3 mm against *E. coli* and lesser activity with minimum inhibition zone of 6.1 mm against *S. typhimurium*. *S. flexineri*, *S. aureus*, *Xanthomonas*, *B. subtilis*, and *S. pyogens* were also found to be moderately inhibited by the synthetic SDG as displayed in the Table 2.

c. Minimum Inhibitory Concentration (MIC)

The agar dilution method was used to determine the MIC of the synthetic SDG. MIC was defined as the lowest concentration of the test agent that inhibited bacterial growth, as indicated by the absence of turbidity. MIC values range from 100 ppm to 300 ppm as given in Table (3). The test compound was effective against *E. coli* and *Xanthomonas* with MIC of 100 ppm and also it inhibited the growth of *S. aureus* at 150 ppm. *S. typhimurium*, *B. subtilis* and *S. flexneri* were completely inhibited by synthetic SDG at 200, 200, and 300 ppm respectively. The minimum concentration of the synthetic SDG that inhibits the growth of the tested organism in comparison to the antibacterial standard chloramphenicol was determined and listed in the Table (3) below. All the concentrations of the synthetic SDG showed strong activity against all the test organisms on concentration dependent manner.

The assessment of antibacterial properties associated with synthetic SDG was accomplished against important pathogenic bacteria in comparison to some antibacterial standards. The synthetic SDG was found to be a worthy antibacterial agent as it showed higher activity against *E. coli* when compared with other microorganisms either in agar well or disk diffusion assay. It also showed high inhibitory activities at minimum concentration against *E. coli* as well as against *Xanthomonas*. The activities of synthetic SDG against bacteria may be indicative to the broad spectrum activities. The phenolic chemical structure of SDG helps justify its antibacterial activity against various bacterial strains. In other words, presence of electron donating groups, methoxy group at Meta position and hydroxyl group at Para position in our target compound (SDG) have revealed good antimicrobial activity against these sorts of bacteria. As reported earlier, phenolic compounds at low concentration affect enzyme activity, especially of those enzymes associated with energy production, while at greater concentrations they cause protein denaturation. Furthermore, Mundt *et al* [33]. reported that, the effect of phenolic compounds on microbial growth could be the result of the ability of these compounds to alter microbial cell permeability, permitting the loss of macro-molecules from the interior and these compounds could also interact with membrane proteins causing a deformation in their structure and functionality as well as affecting cellular activity.

The *in vitro* activity of synthetic SDG against Gram-positive and Gram negative bacteria indicates that this compound could be used against the most common pathogens. However, it must be further studied in animal models to determine their full spectrum of efficacy *in vivo* and also possible toxicity, and to

elucidate their mechanisms of action. However, the present study of in vitro antimicrobial evaluation of synthetic SDG forms a primary platform for further phytochemical and pharmacological studies.

4. CONCLUSION

From the present study it can be concluded that, an efficient route for the synthesis of SDG was achieved and also the characterization of these compounds was discussed. The preliminary antimicrobial activities of the synthetic SDG showed a broad spectrum of activity against clinically important pathogenic bacteria responsible for causing most common bacterial diseases. This antibacterial effect of the synthetic SDG against these panels of vital pathogenic bacteria can be a preferred supplement due to its known health benefits as an antibacterial agent. It would also assist for development of a new alternative medicine system which has no side effects and opens the possibility of finding new clinically effective antimicrobial compounds and production of new antibiotics. It is essential that the research should be continued to use this promising compound in experimental animals and carefully investigate and elucidate its mechanism of action.

REFERENCES

1. Service F. Antibiotics that Resist Resistance. *Scien.* 1995; (270): 724-727.
2. Westh H, Zinn S, Rosdahl T. An international multicenter study of antimicrobial consumption and resistance in *Staphylococcus aureus* isolates from 15 hospitals in 14 countries. *Microb. Drug Resist.* 2004; (10): 169-176.
3. Bandow E, Brotz H, Leichert I. Proteomic approach to understanding antibiotic action. *Antimicrob. Agents Chemother.* 2003; (47): 948-955.
4. Rojas R, Bustamante B, Bauer J. Antimicrobial activity of selected Peruvian medicinal plants. *J. Ethnopharmacol.* 2003; (88): 199- 204.
5. Sharon R, Thompson U. Phytoestrogens and Lignans: Effects on reproduction and chronic disease. *Antinutrients and Phytochemicals in Food.* *Am. Chem. Soc.* 1997; (16): 273-293.
6. Marina T, Anne M, Agnès F, Maryvonne N, Marie-Christine R, Françoise CJ. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. *Natl. Cancer Inst.* 2007; (99): 475-86.


- 287 7. Saleem M, Kim H, Ali M, Lee Y. An update on bioactive plant lignans. *Nat. Prod. Rep.* 2005; (22):
288 696-716.
- 289 8. Thompson L. Experimental studies on lignans and cancer. *Baillieres Clin. Endocrin. Metabo.* 1998;
290 (12): 691- 705.
- 291 9. Moujir L, Seca A, Silva A, López M, Padilla N, Cavaleiro J, Neto C. Cytotoxic activity of lignans from
292 *Hibiscus cannabinus*. *Fitoterapia.* 2007; (78): 385-387.
- 293 10. Barbary M, El-sohaimy A, El-saadani A, Zeitoun M. Antioxidant, Antimicrobial and anti-HCV
294 activities of lignan extracted from flaxseed. *J. Agri. Biol. Sci.* 2010; (6): 247-256.
- 295 11. Obermeyer WR, Musser SM, Betz JM, Casey RE, Pohland AE, Page SW. Chemical
296 studies of phytoestrogens and related compounds in dietary supplements : Flax and Chaparral.
297 *Proc. Soc. Exp. Biol. Med.* 1995; 208:6-12.
- 298 12. Rickard, S.; Thompson, Health effects of flaxseed mucilage. *L. Inform.* 1997; (8): 860- 865.
- 299 13. Rajesha J, Ranga A, Madhusudhan B, Karuna M. Antibacterial properties of secoisolariciresinol
300 diglucoside isolated from Indian flaxseed cultivars. *Curr. Trends Biotechnol. Pharm.* 2010; (4): 551-
301 560.
- 302 14. Rajesha J, Kotamballi N, Chidambara M, Karun M, Basavaraj M, Gokare R. Antioxidant potentials
303 of flaxseed by in vivo model. *J. Agric. Food Chem.* 2006; (54): 3794-3799.
- 304 15. Prasad, K. Oxidative stress as a mechanism of diabetes in diabetic BB prone rats: Effect of
305 secoisolariciresinol diglucoside (SDG). *Mol. Cell. Biochem.* 2000; (209): 89-96.
- 306 16. Serraino M, Thompson L. Flaxseed supplementation and early markers of colon carcinogenesis.
307 *Cancer Lett.* 1992; (63): 159-65.
- 308 17. Serraino, M.; Thompson, L. The effect of flaxseed supplementation on early risk markers for
309 mammary carcinogenesis. *Cancer Lett.* 1991; (60): 135-142.
- 310 18. Malcolm, O.; Neda, C.; Hope, W.; Harold, A. Effects of flaxseed derivatives in experimental
311 polycystic kidney disease vary with animal gender. *Lipids.* 2006; (41): 1141-1149.
- 312 19. Stasevich O, Mikhaleuk S, Kurchenk V. Isolation of secoisolariciresinol diglucoside from lignan-
313 containing extracts of *Linum usitatissimum* seeds. *Khim. Prir. Soedin.* 2009; (1): 21-23.

- 314 20. Kuijsten A, Arts IC, Vree TB, Hollman PC. Pharmacokinetics of enterolignans in healthy men and
315 women consuming a single dose of secoisolariciresinol diglucoside. J Nutr. 2005;135(4):795-801.
- 316 21. Khamlach, K.; Dhal, R.; Brown, E. Heterocycles. 1990; (31): 2195-2199.
- 317 22. Singh, P.; Singh, D. An elegant synthesis of 6H-benzofuro [3,2-c][1]benzopyran-6- ones.
318 Heterocycles. 1985; (23): 903-90.
- 319 23. Yamu X, Yuanyuan Z, Wei W, Yining D, Rui H Synthesis and bioactivity of erythro-
320 nordihydroguaiaretic acid, threo-(-)- saururenin and their analogues. J. Serb. Chem. Soc. 2010;
321 (75): 1325-1335.
- 322 24. Satoshi Y, Yoshimasa H, Takuya K, Toshiya M. Synthesis and Antioxidant Activity of Olivil-Type
323 Lignans, Biosci. Biotechnol. Biochem. 2005; (69): 113-122.
- 324 25. Sadiq M, Shaukath K, Rajesha. Secoisolariciresinol Diglucoside - A Phytoestrogen Nutraceutical of
325 Flaxseed: Synthesis and Evaluation of Antioxidant Potency. J. Free Rad. Antiox. 2011; (1): 31-38.
- 326 26. Hong, A.; Zhan, U.; Shi, C. Chin. Chem. Lett. 2003; (14): 371-374.
- 327 27. Arvind N, Sunil C, Sachin S, Asish B. Prosess for regioselective demethylation of p-methoxy group
328 in phenolic ester and diaryl ketone moieties. US. 2006; (7): 218B2.
- 329 28. Bauer W, Kirby M, Sherris C. Antibiotic susceptibility testing by a standardized single disk method.
330 Am. J. Clin. Pathol. 1966: (45): 493-496.
- 331 29. Parekh J, Chanda S. In-vitro Antimicrobial Activities of Extracts of Launaea procumbens Roxb.
332 (Labiateae), Vitis vinifera L. (Vitaceae) and Cyperus rotundus L. (Cyperaceae) Afric. J. Biomed.
333 Res. 2006; (9): 89-93.
- 334 30. Dufour M, Simmonds S. Bremer. Development of a method to quantify in vitro the synergistic
335 activity of natural antimicrobials. J. Int. J. Food Microbiol. 2003; (85): 249-258.
- 336 31. Gary, D.; Ryszard, A.; Ronald, P. Food Microbiol. 2003; (20): 211-216.
- 337 32. Mundt S, Kreitlow S, Jansen R. Fatty acids with antibacterial activity from the
338 cyanobacterium Oscillatoria redekei HUB 051. J. Appl. Phycol. 2003; (15): 263-267.

339

340

341



342

343

344 **Scheme 1- Schematic representation of synthesis**

345 **Schematic representation for the Reagents and conditions used in the synthesis of SDG and various**

346 **intermediates:** (i) NBS, CCl₄, reflux, 11 h; (ii) 1,4- butanediol, n-But Li, DMF, mix together - 60 °C – 05 °C, 13 h; (iii)

347 2,3,4,6 tetra-o-acetyl α-D glucopyranosyl bromide, HCl, ethanol, reflux, 19 h; (iv) NaOH, ethanol, diethylether; (v)

348 dichloromethane, stannous chloride, stirred, 3 h, 40 °C, 2 N HCl.




Figure 1- Chemical structure of SDG

Chemical structure of SDG skeleton represents the position of the carbon and hydrogen atoms.

Tables

Table 1- Agar-well diffusion

Antibacterial activity of synthetic SDG against some bacteria using agar-well diffusion method.

compound	Conc.	Microorganisms						
		Diameter of zone of inhibition (mm)						
		S.typhimurium	E.coli	S. flexineri.	S. aureus.	Xanthomonas	B. subtilis	S. pyogens
Streptomycin	30 µg/mL	25 ± 0.12	34 ± 0.09	34 ± 0.16	26 ± 0.20	32 ± 0.15	23 ± 0.23	30 ± 0.05
Syn. SDG	2.5 mg/mL	18 ± 0.34	30 ± 0.21	17 ± 0.31	23 ± 0.14	12 ± 0.17	21.4 ± 0.53	7 ± 0.11
Methanol	50 µL	-	-	-	-	-	-	-

*Each value represents mean of three different observations ± S.D. (-) - no zone of inhibition observed, **Streptomycin** - as positive control, **Methanol** - as negative control.

Table 2- Agar-disc diffusion

Antibacterial activity of Synthetic SDG against some bacteria using agar disc-diffusion method.

Compound	Conc.	Microorganisms						
		Diameter of zone of inhibition (mm)						
		S. typhimurium.	E. coli	S. flexineri.	S. aureus.	Xanthomonas.	B. subtilis	S. pyogens.

Streptomycin	30 µg/mL	27.2 ± 0.10	29.1 ± 0.20	25.8 ± 0.09	26.3 ± 0.30	27.1 ± 0.17	20.6 ± 0.24	32.2 ± 0.43
Syn. SDG	2.5 mg/mL	6.1 ± 0.32	27.3 ± 0.10	23 ± 0.27	15.7 ± 0.54	21.2 ± 0.22	19.3 ± 0.19	10.2 ± 0.51
DMSO	50 µL	-	-	-	-	-	-	-

*Each value represents mean of three different observations ± S.D. (-) - no zone of inhibition observed, **Streptomycin** - as positive control, **DMSO** - as negative control

Table 3- MIC values

MIC values for Chloramphenicol as well as synthetic SDG against several bacteria.

compound	Microorganisms MIC (ppm)						
	S. typhimurium	E. coli	S. flexineri.	S. aureus.	Xanthomonas.	B. subtilis	S. pyogens.
Chloramphenicol	100	150	200	200	250	150	100
Syn. SDG	200	100	300	150	100	200	200

*Chloramphenicol was used as positive control.